N@N

Market Maker Surveillance Report. PRKR, NURO, CBMX, RPRX, WH, ALIM, Winning Stocks With Lowest Price Friction For Thursday, Fe

February 21, 2013 / M2 PRESSWIRE / BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Thursday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Thursday there were 4014 companies with "abnormal" market making, 1704 companies with positive Friction Factors and 3708 companies with negative Friction Factors. Here is a list of the top companies with the largest percentage gain per share Thursday and low price friction (bullish). This means that there was more buying than selling in the stocks and their stock prices rose faster with less Friction. Parkervision Inc (NASDAQ:PRKR), NeuroMetrix Inc (NASDAQ:NURO), CombiMatrix Corp (NASDAQ:CBMX), Repros Therapeutics Inc (NASDAQ:RPRX), WSP Holdings Ltd (NYSE:WH), Alimera Sciences Inc (NASDAQ:ALIM). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net .

Market Maker Friction Factor is shown in the chart below:

  Symbol  Change    Percent   Buy Volume   Buy %%    Sell Volume  Sell %%   Net Volume   Friction
  PRKR    $1.780    73.25%    6,241,063    56.03%    4,831,655    43.38%    1,409,408    7,918   
  NURO    $0.680    29.20%    142,146      51.05%    135,472      48.66%    6,674        98      
  CBMX    $3.940    137.76%   5,864,242    53.21%    5,116,290    46.42%    747,952      1,898   
  RPRX    $2.510    24.66%    2,516,372    48.62%    2,366,755    45.73%    149,617      596     
  WH      $1.360    85.00%    109,650      21.86%    94,500       18.84%    15,150       111     
  ALIM    $0.650    24.81%    107,647      62.41%    64,733       37.53%    42,914       660     

Analysis of the Friction Factor chart above shows that each of the six stocks mentioned above have high net buy volumes (buy volume, sell volume) and low price friction in their stocks. The Friction Factor displays how many more shares of buying than selling are required to move a stock higher by one cent or how many more shares of selling than buying moves a stock lower by 1 cent.

For example, the chart above shows PRKR with a dollar gain Thursday of $1.78000 and a Friction Factor of 7,918 shares. That means that it only took 7,918 more shares of buying than selling to move PRKR higher by one penny. The Market Makers are currently allowing the stock to rise quickly (low friction). The combination of low friction and positive market direction can drive prices higher much faster than normal.

Parkervision Inc (NASDAQ:PRKR) - Parkervision, Inc. engages in the design, development, and marketing of proprietary radio frequency (RF) technologies and products for use in semiconductor circuits for wireless communication products in the United States. The company provides its technologies for processing RF waveforms in wireless applications. Its technology applies to transmit and receive functions of a radio transceiver. The transmit portion of the technology, Direct2Power, enables the transformation of a baseband data signal to an RF carrier waveform at the desired power output level in a single unified operation. The receiver portion of the technology, Direct2Data, enables the direct conversion of an RF carrier to a baseband data signal. It also provides engineering consulting and design services to its customers to assist them in developing prototypes and/or products incorporating its technologies. The company focuses on incorporating its technologies into mobile handsets, as well as to other wireless products that are related to networks serving mobile handsets, such as data cards, femtocells, and machine-to-machine and embedded applications. The company s technology is also used in non-cellular radio applications comprising military radios and cable modems. It serves mobile handset manufacturers and their chipset suppliers in the mobile handset industry. The company was founded in 1989 and is headquartered in Jacksonville, Florida..

NeuroMetrix Inc (NASDAQ:NURO) - NeuroMetrix, Inc., a science-based health care company, develops and markets products for the detection, diagnosis, and monitoring of peripheral nerve and spinal cord disorders, such as those associated with diabetes, carpal tunnel syndrome, lumbosacral disc disease, and spinal stenosis. The company focuses on the diagnosis and treatment of neurological complications of diabetes, including diabetic peripheral neuropathy (DPN) and median neuropathy. Its marketed products include the ADVANCE NCS/EMG system, a platform for the performance of traditional nerve conduction studies and invasive electromyography procedures for the diagnosis and evaluation of CTS, low back and leg pain, and DPN; and the NC-stat DPNCheck, a device used to evaluate systemic neuropathies, such as DPN at the point-of-care, as well as consumables and accessories for use with its neurodiagnostic equipment. The company is also developing SENSUS pain therapy device, a transcutaneous electrical nerve stimulator used in the management of chronic pain, such as that caused by DPN; and ADVANCE CTS, a version of the ADVANCE NCS/EMG device for the detection of CTS in people with diabetes. The company distributes its products directly through its direct sales force and independent sales representatives to physicians, clinics, and hospitals consisting of primary care, internal medicine, orthopedic and hand surgeons, pain medicine physicians, neurologists, physical medicine and rehabilitation, physicians, and neurosurgeons, as well as endocrinology/podiatry market in the United States and internationally. NeuroMetrix, Inc. was founded in 1996 and is headquartered in Waltham, Massachusetts..

CombiMatrix Corp (NASDAQ:CBMX) - CombiMatrix Corporation, a molecular diagnostics company, operates primarily in the field of genetic analysis and molecular diagnostics. The company, through its subsidiary, CombiMatrix Molecular Diagnostics, Inc., operates a diagnostics reference laboratory that provides DNA-based clinical diagnostic testing services to physicians, hospitals, clinics, and other laboratories in the areas of pre-and postnatal development disorders, and hematology/oncology genomics. Its developmental disorder suite of array tests focus on the prenatal and postnatal application of array-comparative genomic hybridization (aCGH) in diagnosing genomic syndromes associated with developmental delays, autism spectrum disorders, dysmorphic features, and/or birth defects. The company s oncology diagnostic tests include DNAarray Heme Profile test, which addresses common hematological malignancies with an emphasis on chronic lymphocytic leukemia; DNAarray HER2 PRO, which determines HER2 status; and DNAarray Tumor Profile for DNA-based genomic analysis of solid tumors, including breast, colon, lung, prostate, and brain tumors. CombiMatrix Corporation provides its services primarily through the use of aCGH, which enables the analysis of genetic anomalies, as well as through other test offerings, including fluorescent in-situ hybridization and G-Band Chromosome analysis. Its customers include healthcare institutions, such as hospitals and clinics, physicians, and individual patients; and organizations, such as commercial insurance companies, as well as government payors, including Medicare and Medicaid. The company was founded in 1995 and is headquartered in Irvine, California..

Repros Therapeutics Inc (NASDAQ:RPRX) - Repros Therapeutics Inc., a development stage biopharmaceutical company, focuses on the development of new drugs to treat hormonal and reproductive system disorders. Its primary product candidate includes Androxal, an orally active proprietary small molecule compound that has completed Phase IIb study in men, which normalizes testicular function for the treatment of low testosterone due to secondary hypogonadism; and has completed a Phase II clinical trial for the treatment of hypogonadal men with type 2 diabetes. The company also offers Proellex that acts as a selective blocker of the progesterone receptor in women for the treatment of symptoms associated with uterine fibroids and endometriosis. In addition, it provides phentolamine-based product candidates, including VASOMAX for the treatment of male erectile dysfunction. The company was formerly known as Zonagen, Inc. and changed its name to Repros Therapeutics Inc. in May 2006. Repros Therapeutics Inc. was founded in 1987 and is based in The Woodlands, Texas..

WSP Holdings Ltd (NYSE:WH) - WSP Holdings Limited, through its subsidiaries, manufactures and sells oil country tubular goods. The company offers American Petroleum Institute (API) products, which are the products manufactured according to the standards formulated by the API; and non-API products that are products tailor-made to meet customers specifications. Its products include casing, tubing, and drill pipes that are used for oil and natural gas exploration, drilling, and extraction activities, as well as line pipes, green pipes, iron ore pellets, steel billets, and other unfinished products. The company serves oilfields in China, North America, South America, the Middle East, Asia, Africa, and Russia primarily through distributors and sales agents. WSP Holdings Limited was founded in 1999 and is headquartered in Wuxi, China..

Alimera Sciences Inc (NASDAQ:ALIM) - Alimera Sciences, Inc., a biopharmaceutical company, engages in the research, development, and commercialization of prescription ophthalmic pharmaceuticals. The company focuses on diseases affecting the back of the eye or retina. The company s principal product candidate is ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and could lead to severe vision loss and blindness. Its ILUVIEN is inserted in the back of the patient s eye to a placement site that takes advantage of the eye s natural fluid dynamics to deliver the corticosteroid fluocinolone acetonide. The company is also conducting three Phase III clinical trials on ILUVIEN for the treatment of the dry form of age-related macular degeneration (AMD), the wet form of AMD, and retinal vein occlusion. In addition, it is developing ILUVIEN Applicator, a custom insertion system for ILUVIEN. Alimera Sciences, Inc. was founded in 2003 and is headquartered in Alpharetta, Georgia..

About BUYINS.NET

BUYINS.NET, www.buyins.net , monitors trading in all US stocks in real time and maintains massive databases of short sale and naked short sale time and sales data, short squeeze SqueezeTrigger prices, market maker price movements, shareholder data, statistical data on earnings, sector correlation, seasonality, hedge fund trading strategies, comparable valuations. Reports include:

REGULATORY & COMPLIANCE NEWS

Friction Factor -- market maker surveillance system tracking Level II market makers in all stocks to determine Price Friction and compliance with new "Fair Market Making Requirements"

RegSHO Naked Shorts -- tracks EVERY failure to deliver in all US stocks and tracks all Threshold Security Lists daily for which stocks have naked shorts that are not in compliance with Regulation SHO

INVESTMENTS & TRADING

SqueezeTrigger -- 29 billion cell database tracks EVERY short sale (not just total short interest) in all US stocks and calculates volume weighted price that a short squeeze will begin in each stock.

Earnings Edge -- predicts probability, price move and length of move before and after all US stock earnings reports.

Seasonality -- predicts probability, price move and length of move based on exact time of year for all US stocks.

Group Trader -- tracks sector rotation and stock correlation to its sector and predicts future moves in ALL sectors and industry groups.

Pattern Scan -- automates tracking of every technical pattern and predicts time and size of move in all stocks.

GATS (Global Automated Trading System) -- tracks all known trading strategies and qualifies and quantifies which are working best in real time.

DISCLAIMER:

BUYINS.NET is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. BUYINS.NET has not been compensated by any of the above mentioned companies. Past performance is not indicative of future results. Please visit our web site, www.buyins.net , for complete risks and disclosures.

Contact:

BUYINS.NET Thomas Ronk 800-715-9999 tom@buyins.net www.buyins.net